• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G filed by Achieve Life Sciences Inc.

    3/11/24 1:44:39 PM ET
    $ACHV
    Biotechnology: In Vitro & In Vivo Diagnostic Substances
    Health Care
    Get the next $ACHV alert in real time by email
    SC 13G 1 achi24in.htm achi24in.htm - Generated by SEC Publisher for SEC Filing  

     

              CUSIP NO. 004468500                       13G                             Page 1 of 14

     

     

                                                                                       UNITED STATES

                                                                  SECURITIES AND EXCHANGE COMMISSION

                                                                              Washington, D.C. 20549

     

                                                                                        SCHEDULE 13G

     

                                                           Under the Securities Exchange Act of 1934

                                                                                   (Amendment No. )*

     

                                                                         Achieve Life Sciences, Inc.

                                                                                    (Name of Issuer)

     

                                                                      Common Stock, par value $0.001

                                                                      (Title of Class of Securities)

     

                                                                                           004468500

                                                                                      (CUSIP Number)

     

                                                                                   February 29, 2024

                                             (Date of Event Which Requires Filing of this Statement)

     

                 Check the appropriate box to designate the rule pursuant to which this Schedule is

                 filed:

                 [X] Rule 13d‑1(b)

                 [ ] Rule 13d‑1(c)

                 [ ] Rule 13d‑1(d)

     

                 *The remainder of this cover page shall be filled out for a reporting person's

                 initial filing on this form with respect to the subject class of securities, and

                 for any subsequent amendment containing information which would alter the

                 disclosures provided in a prior cover page.

     

                 The information required in the remainder of this cover page shall not be deemed to

                 be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934

                 ("Act") or otherwise subject to the liabilities of that section of the Act but

                 shall be subject to all other provisions of the Act (however, see the Notes).

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 2 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.

     

                          Franklin Resources, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          Delaware

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.     SOLE VOTING POWER

     

                                        (See Item 4)

     

                          6.     SHARED VOTING POWER

     

                                        (See Item 4)

     

                          7.     SOLE DISPOSITIVE POWER

     

                                        (See Item 4)

     

                          8.     SHARED DISPOSITIVE POWER

     

                                        (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         4,365,7551

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          12.0%

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, CO (See Item 4)

     

     


    1 Includes 2,181,025 shares of Common Stock issuable on the exercise of warrants.

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 3 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Charles B. Johnson2

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                     (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                     (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                     (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                     (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                        (See Item 4)

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                         CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                         (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                         HC, IN (See Item 4)

     

     


    2 shares of common stock of Franklin Resources, Inc. held in a revocable trust for which Mr. C.B. Johnson is trustee, as well as shares held in 401(k) Plan, shares held in an individual retirement account, and shares held by three private charitable foundations for which he is a trustee with shared voting and investment power (Mr. C.B. Johnson disclaims beneficial ownership of such shares).

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 4 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Rupert H. Johnson, Jr.3

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          USA

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      (See Item 4)

     

                          6.    SHARED VOTING POWER

     

                                      (See Item 4)

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      (See Item 4)

     

                          8.    SHARED DISPOSITIVE POWER

     

                                      (See Item 4)

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         (See Item 4)

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          (See Item 4)

     

              12.   TYPE OF REPORTING PERSON

     

                          HC, IN (See Item 4)

     

     


    3 shares of common stock of Franklin Resources, Inc. held in a revocable trust for which Mr. R. H. Johnson, Jr. is trustee, as well as shares held in 401(k) Plan, shares held in an individual retirement account, shares held by his spouse (Mr. R. H. Johnson, Jr. disclaims beneficial ownership of such shares), and shares held by a private charitable foundation for which he is a trustee (Mr. R. H. Johnson, Jr. disclaims beneficial ownership of such shares).

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 5 of 14

     

     

              1.    NAMES OF REPORTING PERSONS.    

     

                          Franklin Advisers, Inc.

     

              2.    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

                          (a)

                          (b) X

     

              3.    SEC USE ONLY

     

              4.    CITIZENSHIP OR PLACE OF ORGANIZATION

     

                          California

     

              NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH:

     

                          5.    SOLE VOTING POWER

     

                                      4,365,755

     

                          6.    SHARED VOTING POWER

     

                                     0

     

                          7.    SOLE DISPOSITIVE POWER

     

                                      4,365,755

     

                          8.    SHARED DISPOSITIVE POWER

     

                                     0

     

              9.    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

                         4,365,755

     

              10.   CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES

                          CERTAIN SHARES [ ]

     

              11.   PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

                          12.0%

     

              12.   TYPE OF REPORTING PERSON

     

                          IA, CO (See Item 4)

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 6 of 14

     

     

              Item 1.

     

              (a)   Name of Issuer

     

                          Achieve Life Sciences, Inc.

     

              (b)   Address of Issuer's Principal Executive Offices

              

               22722 29th Dr. SE, Suite 100

               Seattle, WA  98021

             

         Item 2.

     

              (a)   Name of Person Filing

     

                          (i):   Franklin Resources, Inc.

     

                          (ii):  Charles B. Johnson

     

                          (iii): Rupert H. Johnson, Jr.

     

                          (iv):  Franklin Advisers, Inc.

     

     

              (b)   Address of Principal Business Office or, if none, Residence

     

                          (i), (ii), and (iii):

                          One Franklin Parkway

                          San Mateo, CA 94403‑1906

     

                          (iv):  One Franklin Parkway

                                        San Mateo, CA  94403‑1906

     

              (c)   Citizenship

     

                          (i):     Delaware

     

                          (ii) and (iii): USA

                          (iv): California

     

              (d)   Title of Class of Securities

     

                          Common Stock, par value $0.001

     

              (e)   CUSIP Number

     

                          004468500

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 7 of 14

     

     

              Item 3. If this statement is filed pursuant to §§240.13d‑1(b) or 240.13d‑2(b) or (c),

                              check whether the person filing is a:

                            (a) [ ] Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o).

     

                            (b) [ ] Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c).

                            (c) [ ] Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C.

                                            78c).

     

                            (d) [ ] Investment company registered under section 8 of the Investment Company

                                            Act of 1940 (15 U.S.C 80a‑8).

     

                            (e) [X] An investment adviser in accordance with §240.13d‑1(b)(1)(ii)(E);

     

                            (f) [ ] An employee benefit plan or endowment fund in accordance with

                                            §240.13d‑1(b)(1)(ii)(F);

     

                            (g) [X] A parent holding company or control person in accordance with

                                            §240.13d‑1(b)(1)(ii)(G);

     

                            (h) [ ] A savings associations as defined in Section 3(b) of the Federal Deposit

                                            Insurance Act (12 U.S.C. 1813);

     

                            (i) [ ] A church plan that is excluded from the definition of an investment

                                            company under section 3(c)(14) of the Investment Company Act of 1940 (15

                                            U.S.C. 80a‑3);

     

                            (j) [ ] A non‑U.S. institution in accordance with §240.13d‑1(b)(ii)(J);

     

                            (k) [ ] Group, in accordance with §240.13d 1(b)(1)(ii)(K).

     

                            If filing as a non‑U.S. institution in accordance with §240.13d‑1(b)(1)(ii) (J).

                            please specify the type of institution:

     

              Item 4. Ownership

     

                The securities reported herein are beneficially owned by one or more open or closed end

                investment companies or other managed accounts that are investment management clients of

                investment managers that are direct and indirect subsidiaries (each, an “Investment

                Management Subsidiary” and, collectively, the “Investment Management Subsidiaries”) of

                Franklin Resources Inc. (“FRI”), including the Investment Management Subsidiaries listed

                in this Item 4.  When an investment management contract (including a sub advisory

                agreement) delegates to an Investment Management Subsidiary investment discretion or

                voting power over the securities held in the investment advisory accounts that are

                subject to that agreement, FRI treats the Investment Management Subsidiary as having sole

                investment discretion or voting authority, as the case may be, unless the agreement

                specifies otherwise. Accordingly, each Investment Management Subsidiary reports on

                Schedule 13G that it has sole investment discretion and voting authority over the

                securities covered by any such investment management agreement, unless otherwise noted in

                this Item 4.  As a result, for purposes of Rule 13d‑3 under the Act, the Investment

                Management Subsidiaries listed in this Item 4 may be deemed to be the beneficial owners

                of the securities reported in this Schedule 13G.

     

                Beneficial ownership by Investment Management Subsidiaries and other FRI affiliates is

                being reported in conformity with the guidelines articulated by the SEC staff in Release

                No. 34‑39538 (January 12, 1998) (the “1998 Release”) relating to organizations, such as

                FRI, where related entities exercise voting and investment powers over the securities

                being reported independently from each other. The voting and investment powers held by

                each of FRI’s affiliates whose ownership of securities is disaggregated from that of FRI

                in accordance with the 1998 Release (“FRI Disaggregated Affiliates”) are exercised

               independently from FRI and from all other Investment Management Subsidiaries (FRI, its

          affiliates and the Investment Management Subsidiaries other than FRI Disaggregated

          Affiliates are collectively, “FRI Aggregated Affiliates”). Furthermore, internal policies

          and procedures of, on the one hand, FRI Disaggregated Affiliates, and, on the other hand,

          FRI establish informational barriers that prevent the flow among, on the one hand, FRI

          Disaggregated Affiliates (including preventing the flow between such entities), and, on

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 8 of 14

     

              the other hand, the FRI Aggregated Affiliates of information that relates to the voting

              and investment powers over the securities owned by their respective investment management

              clients. Consequently, FRI Disaggregated Affiliates report the securities over which they

              hold investment and voting power separately from the FRI Aggregated Affiliates for

              purposes of Section 13 of the Act.

     

              Charles B. Johnson and Rupert H. Johnson, Jr. (the “Principal Shareholders”) each own in

              excess of 10% of the outstanding common stock of FRI and are the principal stockholders

              of FRI.  FRI and the Principal Shareholders may be deemed to be, for purposes of Rule

              13d‑3 under the Act, the beneficial owners of securities held by persons and entities for

              whom or for which FRI subsidiaries provide investment management services.  The number of

              shares that may be deemed to be beneficially owned and the percentage of the class of

              which such shares are a part are reported in Items 9 and 11 of the cover pages for FRI

              and each of the Principal Shareholders. FRI, the Principal Shareholders and each of the

              Investment Management Subsidiaries disclaim any pecuniary interest in any of such

              securities. In addition, the filing of this Schedule 13G on behalf of the Principal

              Shareholders, FRI and the FRI Aggregated Affiliates, as applicable, should not be

              construed as an admission that any of them is, and each of them disclaims that it is, the

              beneficial owner, as defined in Rule 13d‑3, of any of the securities reported in this

              Schedule 13G.

     

              FRI, the Principal Shareholders, and each of the Investment Management Subsidiaries

              believe that they are not a “group” within the meaning of Rule 13d‑5 under the Act and

              that they are not otherwise required to attribute to each other the beneficial ownership

              of the securities held by any of them or by any persons or entities for whom or for which

              the Investment Management Subsidiaries provide investment management services.

     

                        (a)     Amount beneficially owned:

     

                                       4,365,755

     

                        (b)     Percent of class:

     

                                        12.0%

     

                        (c)     Number of shares as to which the person has:

     

                                    (i)  Sole power to vote or to direct the vote

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

                                              Franklin Advisers, Inc.:                                  4,365,755

     

                                  (ii)  Shared power to vote or to direct the vote                               0

     

     

                                (iii)  Sole power to dispose or to direct the disposition of

     

                                              Franklin Resources, Inc.:                                         0

     

                                              Charles B. Johnson:                                               0

     

                                              Rupert H. Johnson, Jr.:                                           0

     

                                              Franklin Advisers, Inc.:                                  4,365,755

     

                                   (iv)  Shared power to dispose or to direct the disposition of                0

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 9 of 14

     

     

              Item 5.  Ownership of Five Percent or Less of a Class

     

                               If this statement is being filed to report the fact that as of the date hereof

                               the reporting person has ceased to be the beneficial owner of more than five

                               percent of the class of securities, check the following [ ]. 

     

             

           Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

                               The clients of the Investment Management Subsidiaries, including investment

                               companies registered under the Investment Company Act of 1940 and other managed

                               accounts, have the right to receive or power to direct the receipt of dividends

                               from, and the proceeds from the sale of, the securities reported herein.

     

                  Franklin Biotechnology Discovery Fund, a series of Franklin Strategic Series, an

                  investment company registered under the Investment Company Act of 1940, has an

                  interest in 4,362,050 shares, or 12.0% of the class of securities reported

                  herein.

     

     

              Item 7. Identification and Classification of the Subsidiary Which Acquired the Security

                               Being Reported on By the Parent Holding Company

     

                               See Attached Exhibit C

     

              Item 8. Identification and Classification of Members of the Group

     

                               Not Applicable

     

              Item 9. Notice of Dissolution of Group

     

                               Not Applicable

     


     
     

              CUSIP NO. 004468500                       13G                             Page 10 of 14

     

              Item 10.  Certification

     

              By signing below I certify that, to the best of my knowledge and belief, the securities

              referred to above were acquired and are held in the ordinary course of business and

              were not acquired and are not held for the purpose of or with the effect of changing or

              influencing the control of the issuer of the securities and were not acquired and are

              not held in connection with or as a participant in any transaction having that purpose

              or effect, other than activities solely in connection with a nomination under §

              240.14a‑11.

     

              This report shall not be construed as an admission by the persons filing the report

              that they are the beneficial owner of any securities covered by this report.

     

              Exhibits.

                                Exhibit A Joint Filing Agreement

                                Exhibit B Limited Powers of Attorney for Section 13 Reporting Obligations

                                Exhibit C Item 7 Identification and Classification of Subsidiaries

     

                                                                                        SIGNATURE

              After reasonable inquiry and to the best of my knowledge and belief, I certify that the

              information set forth in this statement is true, complete and correct.

     

              Dated:  March 11, 2024

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

             

              By:     /s/THOMAS C. MANDIA

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Thomas C. Mandia

                             Assistant Secretary of Franklin Resources, Inc.

     

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

               

         Franklin Advisers, Inc.

         Franklin Strategic Series on behalf of

                            Franklin Biotechnology Discovery Fund

     

           

     

              By:     /s/ALISON E. BAUR

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                      Alison E. Baur

                Assistant Secretary of Franklin Advisers, Inc.

                Vice President and Assistant Secretary of Franklin Strategic Series

     

     

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 11 of 14

     

     

              EXHIBIT A

     

              JOINT FILING AGREEMENT

     

              In accordance with Rule 13d‑1(k) under the Securities Exchange Act of 1934, as amended,

              the undersigned hereby agree to the joint filing with each other of the attached

              statement on Schedule 13G and to all amendments to such statement and that such statement

              and all amendments to such statement are made on behalf of each of them.

     

              IN WITNESS WHEREOF, the undersigned have executed this agreement on March 11, 2024.

     

              Franklin Resources, Inc.

     

              Charles B. Johnson

     

              Rupert H. Johnson, Jr.

     

             

              By:     /s/THOMAS C. MANDIA

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                             Thomas C. Mandia

                             Assistant Secretary of Franklin Resources, Inc.

     

                             Attorney‑in‑Fact for Charles B. Johnson pursuant to Power of Attorney

                             attached to this Schedule 13G

     

                             Attorney‑in‑Fact for Rupert H. Johnson, Jr. pursuant to Power of Attorney

                             attached to this Schedule 13G

     

               

         Franklin Advisers, Inc.

         Franklin Strategic Series on behalf of

                            Franklin Biotechnology Discovery Fund

     

           

     

              By:     /s/ALISON E. BAUR

                             ‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑‑

                      Alison E. Baur

                Assistant Secretary of Franklin Advisers, Inc.

                Vice President and Assistant Secretary of Franklin Strategic Series

             

                            

     

     

     

     

        

     

     

     

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 12 of 14

     

              EXHIBIT B

     

                                                                                           EXHIBIT B

    LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

              Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023.

     

     

                                                                                                                                  /s/CHARLES B. JOHNSON

                                                                                                                                  Signature

                                                                                                                                  Charles B. Johnson ___

                                                                                                                                  Print Name

     

     

     


     
     

     

              CUSIP NO. 004468500                       13G                             Page 13 of 14

     

     

              LIMITED POWER OF ATTORNEY

    FOR SECTION 13 AND 16 REPORTING OBLIGATIONS

     

         Know all by these presents, that the undersigned hereby makes, constitutes and appoints each of Alison E. Baur, Thomas C. Mandia, Beth McAuley O’Malley, Thomas C. Merchant, Kimberly H. Novotny, Virginia E. Rosas and Navid J. Tofigh each acting individually, as the undersigned’s true and lawful attorney-in-fact, with full power and authority as hereinafter described on behalf of and in the name, place and stead of the undersigned to:

         1. prepare, execute, acknowledge, deliver and file Forms ID, Schedules 13D and 13G, and Forms 3, 4 and 5 (including any amendments thereto and any related documentation) with the United States Securities and Exchange Commission and any national securities exchanges relating to Franklin Resources, Inc. (“FRI”) and/or any registered closed-end company to which an affiliate of FRI is an investment adviser (each, a “Reporting Entity”), as considered necessary or advisable under Regulation S-T and Sections 13(d) and 16(a) of the Securities Exchange Act of 1934 and the rules and regulations promulgated thereunder, as amended from time to time (the “Exchange Act”); and

         2. seek or obtain, as the undersigned’s representative and on the undersigned’s behalf, information on transactions in the securities of any Reporting Entity from any person, including brokers, employee benefit plan administrators and trustees, and the undersigned hereby authorizes any such person to release any such information to the undersigned and approves and ratifies any such release of information; and

         3. perform any and all other acts which in the discretion of such attorney-in-fact are necessary or desirable for and on behalf of the undersigned in connection with the foregoing.

         The undersigned acknowledges that:

         1. this Limited Power of Attorney authorizes, but does not require, each such attorney-in-fact to act in their discretion on information provided to such attorney-in-fact without independent verification of such information;

         2. any documents prepared and/or executed by any such attorney-in-fact on behalf of the undersigned pursuant to this Limited Power of Attorney will be in such form and will contain such information and disclosure as such attorney-in-fact, in his or her discretion, deems necessary or desirable;

         3. none of FRI, any Reporting Entity nor any of such attorneys-in-fact assumes (i) any liability for the undersigned’s responsibility to comply with the requirements of the Exchange Act, (ii) any liability of the undersigned for any failure to comply with such requirements, or (iii) any obligation or liability of the undersigned for profit disgorgement under Section 16(b) of the Exchange Act; and

         4. this Limited Power of Attorney does not relieve the undersigned from responsibility for compliance with the undersigned’s obligations under the Exchange Act, including without limitation, the reporting requirements under Section 16 of the Exchange Act.

         The undersigned hereby gives and grants each of the foregoing attorneys-in-fact full power and authority to do and perform all and every act and thing whatsoever requisite, necessary or appropriate to be done in and about the foregoing matters as fully to all intents and purposes as the undersigned might or could do if present, hereby ratifying all that each such attorney-in-fact of, for and on behalf of the undersigned, shall lawfully do or cause to be done by virtue of this Limited Power of Attorney, and indemnifies each of the foregoing attorneys-in-fact against any loss of any nature whatsoever arising in connection therewith.

         This Limited Power of Attorney shall remain in full force and effect until revoked by the undersigned in a signed writing delivered to each such attorney-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Limited Power of Attorney to be executed as of this 11th day of December, 2023.

     

                                                                                                                            /s/RUPERT H. JOHNSON, JR.

                                                                                                                            Signature

     

                                                                                                                            Rupert H. Johnson, Jr.  

                                                                                                                            Print Name

     


     
     

     

    CUSIP NO. 004468500                             13G                              Page 14 of 14

     

    EXHIBIT C

     

              Franklin Advisers, Inc.                                     Item 3 Classification: 3(e)

     

     

     

     

    Get the next $ACHV alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $ACHV

    DatePrice TargetRatingAnalyst
    11/14/2024$12.00Buy
    Rodman & Renshaw
    9/27/2024$20.00Strong Buy
    Raymond James
    5/10/2023$8.00 → $20.00Buy
    Maxim Group
    10/4/2021$25.00Buy
    Alliance Global Partners
    6/23/2021$23.00Outperform
    Oppenheimer
    More analyst ratings

    $ACHV
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Announces Cytisinicline Phase 3 ORCA-3 Trial Publication on Smoking Cessation in JAMA Internal Medicine

      ORCA-3 Demonstrated a Significant Increase in Quitting and Reduction in Nicotine Cravings for Cytisinicline-Treated Participants Compared to Placebo Cytisinicline New Drug Application (NDA) Submission to FDA Planned for June 2025 SEATTLE and VANCOUVER, British Columbia, April 21, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that complete trial results from its ORCA-3 were published in the Journal of the American Medical Association (JAMA) Internal Medicine. ORCA-3 was the

      4/21/25 11:19:48 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Financials

    Live finance-specific insights

    See more
    • Achieve Life Sciences Reports First Quarter 2025 Financial Results and Highlights Updates in Cytisinicline Program

      Reiterates Planned Submission of an NDA for Cytisinicline to FDA in June 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, May 13, 2025 SEATTLE and VANCOUVER, British Columbia, May 13, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for first quarter 2025 and confirmed that it plans to submit the upcoming New Drug Application (NDA) for cytisinicline to the U.S. Food and Drug Administration (FDA) in June 2025. "The Achieve team is fully

      5/13/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 13, 2025

      SEATTLE and VANCOUVER, British Columbia, May 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV) a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced that it will report its first quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday May 13, 2025, at 8:30 AM EDT. To access the webcast, please use the following link: 1Q25 Earnings Webcast. Alternatively, you may access the live conference call by dialing 877-269-7756 (U.S. & Canada) or 201-689-7817 (International) and r

      5/6/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Reports Financial Results for Fourth Quarter and Year-End 2024 and Provides Update on the Cytisinicline Development Program

      Reiterates Planned Cytisinicline NDA Submission Expected at the End of Q2 2025 Company to Host Conference Call at 8:30 AM EDT Today, Tuesday, March 11, 2025 SEATTLE and VANCOUVER, British Columbia, March 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced its financial results for the fourth quarter and year-end 2024 and reiterated its plans to submit its new drug application (NDA) for cytisinicline at the end of the second quarter of 2025. Recent Hig

      3/11/25 7:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    SEC Filings

    See more
    • SEC Form 10-Q filed by Achieve Life Sciences Inc.

      10-Q - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      5/13/25 7:38:20 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Filer)

      5/13/25 7:34:08 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Amendment: SEC Form SCHEDULE 13G/A filed by Achieve Life Sciences Inc.

      SCHEDULE 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/9/25 1:01:44 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Stewart Richard Alistair bought $45,850 worth of shares (10,000 units at $4.58), increasing direct ownership by 35% to 38,501 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/6/24 4:49:23 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Leadership Updates

    Live Leadership Updates

    See more
    • Achieve Life Sciences Appoints Dr. Kristen Slaoui and Nancy Phelan to its Board of Directors

      SEATTLE and VANCOUVER, British Columbia, Jan. 10, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company focused on the global development and commercialization of cytisinicline for smoking cessation and nicotine dependence, today announced that Kristen Slaoui, Ph.D., and Nancy Phelan will join its Board of Directors. Achieve also announced that current Board member, Vaughn Himes, Ph.D., has retired and resigned from the Board. He will continue to provide consulting services to the company. "We are delighted to welcome Kristen and Nancy to our Board of Directors," said Tom King, Executive Chairman of Achieve's Board of Directors. "Their wea

      1/10/25 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Achieve Life Sciences Appoints Mark Oki as Chief Financial Officer

      SEATTLE and VANCOUVER, British Columbia, Dec. 09, 2024 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (NASDAQ:ACHV), a late-stage pharmaceutical company dedicated to the global development and commercialization of cytisinicline for the treatment of nicotine dependence, today announced that Mark Oki has joined the company as its Chief Financial Officer, effective December 5, 2024. Mr. Oki will oversee the company's financial strategy and operations, including accounting, investor relations, information technology, legal and other key administrative functions, ensuring effective planning and execution to support organizational objectives. "Mark's extensive financial, strategic, and opera

      12/9/24 8:30:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath's Board of Directors

      Delcath Systems, Inc. (NASDAQ:DCTH) (the "Company" or "Delcath"), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce the appointment of Dr. Bridget Martell to the Company's Board of Directors effective May 23, 2024. "We are pleased to welcome Dr. Martell to the Delcath Board," said John Sylvester, Chairman of the Delcath Board of Directors. "Dr. Martell's extensive experience serving both in senior management roles and as a director at multiple biotechnology companies, as well as her expertise in oncology clinical development, will be a great asset to Delcath as we strive to achieve our mission of improving pa

      5/28/24 9:30:00 AM ET
      $ACHV
      $ALGS
      $DCTH
      $PNT
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
      Medical/Dental Instruments

    $ACHV
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Achieve Life Sciences Inc.

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/12/24 12:14:09 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G filed by Achieve Life Sciences Inc.

      SC 13G - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      11/4/24 10:59:37 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form SC 13G/A filed by Achieve Life Sciences Inc. (Amendment)

      SC 13G/A - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Subject)

      5/20/24 5:01:27 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Rodman & Renshaw initiated coverage on Achieve Life Sciences with a new price target

      Rodman & Renshaw initiated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $12.00

      11/14/24 7:20:56 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Raymond James initiated coverage on Achieve Life Sciences with a new price target

      Raymond James initiated coverage of Achieve Life Sciences with a rating of Strong Buy and set a new price target of $20.00

      9/27/24 7:26:18 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Maxim Group reiterated coverage on Achieve Life Sciences with a new price target

      Maxim Group reiterated coverage of Achieve Life Sciences with a rating of Buy and set a new price target of $20.00 from $8.00 previously

      5/10/23 11:34:00 AM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care

    $ACHV
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Chief Financial Officer Oki Mark K bought $28,887 worth of shares (10,000 units at $2.89) (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:38:43 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • Chieve Executive Officer Stewart Richard Alistair bought $28,598 worth of shares (10,000 units at $2.86), increasing direct ownership by 20% to 60,876 units (SEC Form 4)

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      3/19/25 4:32:22 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care
    • SEC Form 4 filed by Principal Accounting Officer Wan Jerry

      4 - ACHIEVE LIFE SCIENCES, INC. (0000949858) (Issuer)

      1/30/25 4:54:30 PM ET
      $ACHV
      Biotechnology: In Vitro & In Vivo Diagnostic Substances
      Health Care